Overview

A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia

Status:
Unknown status

Trial end date:
2019-12-01

Target enrollment:

Participant gender:

Summary

Depression with ongoing insomnia is a common clinical presentation with patients. Clinical data suggests that patients with insomnia that receive concomitant treatment with a sleep aid experience a more robust antidepressant response along with a quicker response. The purpose of this clinical study is to compare the effectiveness of the FDA-approved insomnia medication suvorexant, also known as Belsomra®, as add-on treatment to an antidepressant to that of placebo plus antidepressant treatment in patients with depression and residual or ongoing insomnia.

Phase:

Phase 4

Details

Lead Sponsor:

Institute for Advanced Medical Research, Alpharetta, GA

Collaborators:

Augusta University, Dept. of Psychiatry
Jefferson Medical College of Thomas Jefferson University
Medical College of Georgia at Augusta University, Department of Psychiatry and Health Behavior, Augusta, GA

Treatments:

Antidepressive Agents
Suvorexant